How are participants protected from potential psychological effects of knowing their treatment assignment?

Methods: This Phase 4, multicenter, open label study included patients with uncontrolled gout (SU ≥6 mg/dL, oral urate-lowering therapy intolerance/inefficacy, ... If you receive at least 1 dose of RYZ801, you will enter the Long-Term Follow-Up period following the Study Treatment Stage. During Long-Term Follow-Up, you ... Jun 17, 2023 ... Treatment with amikacin liposome inhalation suspension (ALIS) improve culture conversion in patients with M abscessus pulmonary disease. SAT0471 Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis is More Effective Than Conventional Therapies in Inducing D ... Nitazoxanide co-administered with atazanavir/ritonavir was safe but not better than standard of care in treating COVID-19. Jul 9, 2021 ... Phase 1b open-label trial of afatinib plus Xentuzumab (BI 836845) in patients with EGFR mutation-positive NSCLC after progression on EGFR tyrosine kinase ... Eligibility Requirements. Inclusion Criteria. Subjects must meet all the following criteria for enrollment in the study: - Eastern Cooperative Oncology Group ... Apr 25, 2024 ... "Results from this study show that patients with moderate-to-severe atopic dermatitis can strive for both little to no itch and clearer skin.” 1. An Open-label Trial With Plasma Prekallikrein Oligonucleotide Antisense Therapy To Control Angioedema Attacks In Hereditary Angioedema Patients With Normal C1- ... This prospective, open-label clinical trial aimed to evaluate the tolerability and the efficacy of B cell depletion for remission induction in IgG4-RD.